2024-02-02 12:43:08 ET
Bristol-Myer Squibb Company (BMY)
Q4 2023 Earnings Conference Call
February 2, 2024 08:00 AM ET
Company Participants
Tim Power - VP, IR
Chris Boerner - CEO
David Elkins - EVP & CFO
Sarnit Hirawat - Chief Medical Officer
Adam Lenkowsky - Chief Commercialization Officer
Conference Call Participants
Luisa Hector - Berenberg
Chris Schott - JP Morgan
Andrew Baum - Citi
Seamus Fernandez - Guggenheim
Tim Anderson - Wolfe Research
Trung Huynh - UBS
Geoff Meacham - Bank of America
Matt Phipps - William Blair
Steve Scala - TD Cowen
Terence Flynn - Morgan Stanley
Evan Siegerman - BMO Capital Markets
Carter Gould - Barclays
Robyn Karnauskas - Truist
James Sheehan - Deutsche Bank
Akash Tiwari - Jefferies
Rajesh Kumar - HSBC
Presentation
Operator
Welcome to the Bristol-Myers Squibb Fourth Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Tim Power, Vice President and Head of Investor Relations. Please go ahead.
Tim Power
Thank you, and good morning, everyone. Thanks for joining us this morning for our fourth quarter 2023 earnings call. Joining me this morning with prepared remarks are Chris Boerner, our Chief Executive Officer; and David Elkins, our Chief Financial Officer. Also participating in today's call are Adam Lenkowsky, our Chief Commercialization Officer; and Samit Hirawat, our Chief Medical Officer and Head of Global Drug Development. As you'll note, we've posted slides to bms.com that you can use to follow along with for Chris and David's remarks.
Before we get started, I'll read our forward-looking statement. During this call, we'll make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's SEC filings. These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. We specifically disclaim any obligation to update forward-looking statements even if our estimates change.
We'll also focus our comments on our non-GAAP financial measures, which are adjusted to exclude certain specified items. Reconciliations of certain non-GAAP financial measures to the most comparable GAAP measures are available at bms.com.
And with that, I'll hand it over to Chris.
Chris Boerner
Thanks, Tim, and good morning to all of you. I'm very pleased to be speaking to you on our earnings call for the first-time as a CEO, and I'm excited about the opportunity for our company to continue to deliver transformational medicines for patients....
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb Company (BMY) Q4 2023 Earnings Call Transcript